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VOL.16  NO.5  MAY  2011Editorial
Psychosis, and the Violent 
Psychiatric Patient
Dr. Paul Tat-chung LAM
In this issue we have 5 articles on various aspects of psychosis. Psychosis 
is defined as (1) a cerebral dysfunction, (2) resulting in abnormal 
behavioural symptoms, (3) the patient has gross impairment of reality 
testing and (4) there is loss of insight. Common symptoms of psychosis 
include hallucination, delusion, and acute emotional upset. It can 
be broadly categorised into (1) organic psychosis in which there is 
evident pathology of the brain as detected by traditional examination 
and investigation. Examples include drug and alcoholic intoxication, 
epilepsy, and late stage Alzheimer’s disease, and (2) functional psychosis 
in which there are no obvious pathological changes. Examples are 
schizophrenia and bipolar disorder. Treatment of psychotic patients 
forms a great part of the work of psychiatrists, and poses a very heavy 
burden on hospitals and social personnel and facilities. Recent studies 
have drawn attention to the mechanism of development of the psychotic 
brain, and to the importance of early detection and treatment of the 
condition. It is therefore appropriate for all doctors to have some 
information about current advances and insight into the illness.
Every now and then, perhaps several times in a year, we come across 
local news reports of gruesome incidents of violence committed by 
psychiatric patients. These include murder or serious bodily harm to 
close relatives or innocent people, or self injury, sometimes in the most 
grotesque, bizarre and unimaginable manner. The greatest majority of 
incidents committed by psychiatric patients are carried out by patients 
with psychosis. Following an incident, there are usually sensational 
reports in the media, followed by public outcry. All would then die 
down to await the next incident not too distant in the future. Is this an 
inevitable path? Even our leaders in the local Health Service had come 
out to say that such incidents are bound to occur, and there is not a lot 
that can be done.
However, such an attitude of defeatism is not justified. In Hong Kong 
we have first class psychiatrists, and well trained paramedical personnel 
such as community psychiatric nurses and social workers. We have 
efficacious drugs at our disposal, we also have the hard ware such as 
clinics and hospitals, but we do not have the will power and the service 
system in place to tackle this very pressing issue. There is no doubt that 
the public psychiatric service is grossly overloaded. However there are 
ways to alleviate the situation. Firstly there are many patients with minor 
complaints such as mild anxiety who do not need to be kept under the 
Specialist Psychiatric Clinics. Secondly better utilisation should be made 
of spare capacities of the well trained and vast experience of specialist 
psychiatrists in the private sector. Recently the Hospital Authority allows 
specialist psychiatrists who have left the service to take up part time 
employment. This is certainly a step in the right direction. With some 
relief of the work load, greater efforts can be directed specifically and 
intensively to the group of patients at high risk of violence or suicide, 
and the occurrence of such can be reduced to a minimum. This is 
something that can be done, and must be done as an urgency. 
In preparing this issue of the Medical Diary, I am most indebted to the 
advice and assistance of Professor Eric YH Chen, and to the coordination 
of Dr. Sherry KW Chan of the Dept. of Psychiatry, The University of 
Hong Kong.
Editor
www.apro.com.hk
Dr. Paul Tat-chung LAM
FRCP, FHKAM(Medicine), FHKAM(Psychiatry)
Honorary Clinical Assistant Professor, The University of Hong Kong  
Specialist in Psychiatry
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This article has been selected by the Editorial Board of the Hong Kong Medical Diary for participants in the CME programme of the Medical 
Council of Hong Kong (MCHK) to complete the following self-assessment questions in order to be awarded one CME credit under the programme 
upon returning the completed answer sheet to the Federation Secretariat on or before 31 May 2011.
Rationale and the Local Development of 
Early Intervention for Psychosis
Dr. Wing-chung CHANG 
MRCPsych, FHKCPsych, FHKAM (Psychiatry)
Clinical Assistant Professor, Department of Psychiatry, The University of Hong Kong 
Dr. Wing-chung CHANG
Rationale of Early Intervention for 
Psychotic Disorders
Psychotic disorders including schizophrenia are severe 
mental illnesses that constitute a major public health 
problem. Schizophrenia and schizoaffective disorder 
together rank as the fifth leading cause of disability by 
the World Health Organization (WHO) 1. As psychosis 
typically occurs in late adolescence or early adulthood, 
which is the critical developmental life stage in terms 
of personality, social role, scholastic or vocational 
achievement, it can therefore cause profound adverse 
impact on patients’ long-term functional capacity. 
Besides having debilitating symptoms of delusions, 
hallucinations, loss of volition, social withdrawal and 
neurocognitive impairment, individuals suffering from 
psychosis are also prone to other psychiatric morbidities 
such as depression, substance abuse and suicide. At a 
societal level, enormous economic costs are incurred by 
psychotic disorders through direct medical costs, lost 
employment, increased welfare benefits and diminished 
productivity of caregivers2. 
In the last decade, early intervention for psychotic 
disorders has become a major trend in mental health 
care development worldwide3. This specialised 
programme comprises two key components: 1) early 
detection to reduce delay in treatment and 2) phase-
specific intervention during the early illness stage. A 
large number of studies have found that prolonged 
duration of untreated psychosis (DUP) predicted worse 
symptomatic and functional outcome, and poorer 
quality of life in patients with first-episode psychosis4. 
As literature revealed that prolonged delays of up to 
one to two years before treatment were common in 
individuals experiencing psychosis5, DUP is thus posited 
as a potentially malleable prognostic factor which 
may be reduced by early identification and prompt 
intervention. Research also suggested that the first 
few years of psychotic disorders after onset is a critical 
period for determining long-term illness outcome6. 
Provision of focused and phase-specific intervention at 
this early illness stage may therefore ameliorate, if not 
prevent, potentially pronounced disability. A growing 
body of evidence has indicated that, when compared 
with standard psychiatric service, early intervention 
programmes are associated with shortened treatment 
delay, increased symptomatic remission, lower relapse 
rates, lower use of legal detention, reduced hospital 
admissions, improved psychosocial functioning, better 
service engagement, higher client / carer satisfaction 
and lower suicide rates7. In fact, this phase-specific early 
intervention model has been endorsed by WHO and the 
International Early Psychosis Association which jointly 
issued the “Early Psychosis Declaration” in 20058. 
The Local Development of Early 
Intervention Service for Psychosis
The Early Assessment Service for Young People with 
Psychosis (abbreviated as EASY), which has been 
launched since 2001, is a publicly-funded specialised 
programme that provides early assessment and phase-
specific intervention for all individuals aged 15 to 25 
years experiencing their first-episode psychosis9. The 
programme consists of five treatment teams covering the 
whole territory of Hong Kong. Being one of the first and 
most comprehensive early intervention programmes 
in Asia, the EASY programme comprises three main 
components: 1) to raise public awareness; 2) to create 
an easily accessible referral system and 3) to provide a 
phase-specific intervention. 
In order to improve the mental health literacy to 
psychosis in the general public, a series of public 
education programmes have been organised utilising 
various means of channels including TV, radio 
interviews, press release, public talks, school visits, 
leaflets and exhibitions, to name a few. The EASY 
programme also introduced a more perceptive Chinese 
term for psychosis, namely “思覺失調 ” (literally means 
dysregulation in thinking and perception) to ameliorate 
the stigma. Regarding the referral pathway, a broad 
range of referral mechanisms is implemented to 
encourage early help-seeking in individuals suffering 
from first-episode psychosis. These include a hotline 
direct referral system, referrals from community 
via emails, walk-ins, school social workers and non-
governmental organisations (NGOs), as well as within 
the public health care system. After receiving a referral, 
a telephone-based initial screening assessment is 
carried out by a case manager. An individual who has 
been identified as a potential client for the programme 
will then be thoroughly evaluated by a psychiatrist to 
ascertain the diagnosis and to formulate a management 
plan within one week after screening.  
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The programme adopts a case management approach 
and assertively follows up patients for the first three 
years after their initial episodes (including follow-
up in a transitional step-down clinic in year three). 
Each individual patient is assigned a case manager. 
Standardised clinical assessments measuring symptom 
profiles and psychosocial functioning are performed to 
each patient. Besides optimal psychopharmacotherapy, 
the EASY programme also provides a range of 
protocol-based psychosocial interventions to enhance 
the patient’s psychological adjustment, to minimise 
secondary psychiatric morbidities, to promote illness 
recovery and to alleviate the carer’s stress. These 
include psychoeducation groups for patients and 
families, individual supportive counselling, cognitive 
behavioural therapy for treatment-resistant psychotic 
symptoms and family intervention. The programme also 
has close collaboration with NGOs and local community 
networks to facilitate rehabilitation process of patients 
who are clinically stabilised with treatment. Patients 
will be transferred to a general psychiatric team for 
continuous follow-up at the end of the three-year EASY 
service.
In order to evaluate the effectiveness of the local early 
intervention programme, a large scale three-year follow-
up case-control study was carried out comparing the 
clinical and functional outcome between 700 cases in 
the EASY programme with 700 historical controls who 
received standard care prior to the implementation of 
the programme10. Subjects were individually matched 
for age, sex and diagnosis, and had similar level of 
positive and negative symptoms at presentation. The 
results suggested that the early intervention (EI) group 
had significantly fewer days of hospitalisation, less 
severe positive and negative symptoms, fewer suicides, 
reduced service disengagement and higher likelihood 
of achieving a period of recovery than the control group 
three years after treatment initiation. Additionally, it 
has also been shown that EI is cost-neutral with extra 
personnel costs being offset by reduced inpatient costs9. 
The robust positive findings therefore suggest that key 
elements of the EASY programme have been effective 
for the Hong Kong population. 
Conclusion 
Schizophrenia and other psychotic disorders have long 
been regarded as chronic and debilitating illnesses 
resulting in significant disabilities. The paradigm shift 
from institutional model of care towards community-
based early intervention service delivery changes the 
long-held pessimism attached to psychotic disorders 
to an expectation of a much more positive outlook by 
clinicians, patients and their families. Given that there is 
considerable evidence supporting the adoption of early 
intervention for psychosis and the success of the EASY 
programme, the Government of Hong Kong is going to 
plan for an extension of this early intervention service 
to cover a wider age range (above 25 years of age) 11. It 
is to hope that patients of all ages can benefit from this 
high-quality, cost-effective and non-stigmatising phase-
specific treatment to facilitate their recovery and pursuit 
in education and work. 
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MCHK CME Programme Self-assessment Questions
Please read the article entitled “Rationale and the Local Development of Early Intervention for Psychosis” by 
Dr. Wing-chung CHANG  and complete the following self-assessment questions. Participants in the MCHK 
CME Programme will be awarded 1 CME credit under the Programme for returning completed answer sheets 
via fax (2865 0345) or by mail to the Federation Secretariat on or before 31 May 2011. Answers to questions 
will be provided in the next issue of The Hong Kong Medical Diary.  
Questions 1-10: Please answer T (true) or F (false) 
1. Schizophrenia and schizoaffective disorder together rank as the fifth leading cause of disability by World  
 Health Organization.
 
2. The typical age of onset of psychotic disorders is within 30 to 40 years. 
3. Common psychiatric morbidities of schizophrenia include depression and substance abuse.
4. Prolonged duration of untreated psychosis has been shown by numerous studies to be associated with poor  
 clinical outcome.
5. A significant proportion of patients having psychotic disorders had duration of untreated psychosis of up to  
 one to two years prior to implementation of early intervention service. 
6. Critical period hypothesis stated that the prodrome of psychotic disorders is the prime interval for intervention.
 
7. Literature has demonstrated that early intervention programmes improve symptomatic and functional outcome  
 of patients with psychosis when compared with standard psychiatric service. 
8. The Early Assessment Service for Young People with Psychosis (EASY) programme targets at individuals aged  
 15 to 30 years experiencing their first psychotic episodes.
9. Each patient enrolled in the EASY programme is assigned a case manager and is followed up for three years  
 before transfer to general psychiatric service. 
10. Case-control study revealed that there was no significant difference between the EASY programme and   
 standard care in terms of length of hospitalisations and suicide rate. 
ANSWER SHEET FOR MAY 2011
Answers to April 2011 Issue
Please return the completed answer sheet to the Federation Secretariat on or before 31 May 2011 for 
documentation. 1 CME point will be awarded for answering the MCHK CME programme (for non-specialists) 
self-assessment questions. 
Carbapenem-resistant or Multidrug-resistant Acinetobacter Baumannii - a Clinician’s Perspective
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HKID No.: __ __ - __ __ __ __ X X (X) HKDU No.:  __________________ HKAM No.:  ________________
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Rationale and the Local Development of Early Intervention 
for Psychosis
Dr. Wing-chung CHANG 
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Clinical Assistant Professor, Department of Psychiatry, The University of Hong Kong 
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Relapse in Schizophrenia
Dr. Christy LM HUI 
PhD
Chief Research Officer, Jockey Club Early Psychosis (JCEP) Project, 
Department of Psychiatry, The University of Hong Kong
Dr. Christy LM HUI 
Introduction 
Schizophrenia is characterised not only by its florid and 
extraordinary positive symptoms, but also negative 
and disorganisation symptoms; these symptoms affect 
almost all aspects of mental function in emotion, 
language, motor, as well as perception and reasoning. 
Clinical observations have suggested that there are a 
great variety of courses and outcome in schizophrenia. 
The premorbid and prodromal phase refers to the 
period prior to illness onset in which vulnerability traits 
or subclinical symptoms are expressed, respectively. 
First-episode psychosis refers to the period when a 
patient presents with a diagnosable psychotic disorder 
for the first time, usually characterised by frank 
psychotic symptoms of hallucinations, delusions and 
behavioural disturbances.1 
Outcome is often conceptualised in terms of remission, 
recovery and relapse. Remission is a state when these 
psychotic symptoms subside. Recovery is remission from 
psychotic symptoms, as well as attaining adequate social 
and occupational functioning where some patients can 
achieve. Relapse is usually defined as the re-emergence of 
psychotic symptoms. A 20-year follow-up of the Madras 
study showed that about 40% of patients relapsed with 
complete remission in between, 44% relapsed with 
partial remission in between; and only 8% had complete 
remission.2 Importantly, this long-term follow-up study 
indicated that the level of disability incurred is high 
and relapse is the typical pattern. This article will first 
introduce the concept of relapse and its associated costs, 
followed by investigating both naturalistic and controlled 
studies on the risk of relapse. It will end with a brief 
discussion on the important clinical decision concerning 
medication discontinuation and relapse. 
Defining Relapse
Relapse can be defined more broadly or more narrowly. 
Narrow definition of relapse involves the definite 
re-emergence of psychotic symptoms associated 
with significant disturbance in functioning and 
social behaviour.3 According to Johnstone, relapse 
could also be defined as Type I, the reappearance of 
schizophrenic symptoms in a patient who has been 
free of them following the initial episode, and Type 
II, the exacerbation of persistent positive symptoms.4 
Clinical instruments such as the Positive and Negative 
Syndrome Scale (PANSS), Clinical Global Impressions 
(CGI) and the Brief Psychiatric Rating Scale (BPRS) are 
often used for operationally defining relapse.
In response to these diverse approaches in measuring 
symptoms, some researchers adopt a broader definition 
of relapse, such as ‘rehospitalisation’ being a proxy for 
relapse.5-8 However, rehospitalisation can result from 
a much wider range of other clinical scenarios such as 
suicidal attempt, violence, medication side effects, and 
thus relapse is only one of the many possible causes for 
rehospitalisation. In reality, rehospitalisation is usually 
the most expensive part in the mental health cost for 
psychotic patients, the measurement of rehospitalisation 
would  be  most  re levant  in  hea l th  economics 
considerations.9  
Relapse Costs
Consequence of relapse can be enormous. Medical costs, 
non-medical costs and productivity losses associated 
with relapses are enormous from the economic 
perspective.10-11 Studies have found that patients have 
a poorer response to treatment in subsequent relapse 
episodes, as well as a longer time to remission with each 
subsequent episode.12-14 To the patients, a relapse with 
re-emergence of psychotic symptoms may imply the 
necessity of staying on medication for a considerably 
longer period of time or even on a long-term basis. This 
fact could be particularly devastating to a young patient 
who has been making an otherwise smooth recovery 
from his or her first-episode illness.15 
Relapse Rates: Naturalistic and 
Controlled Studies 
Relapse rates in schizophrenia have been studied 
extensively in both naturalistic and controlled studies. 
Despite the fact that studies varied in relapse definitions 
and duration of follow-up, the risk of relapse is 
still high. Naturalistic studies have found that the 
cumulative relapse rate was 70%-82% up to 5 years 
following the first admission or episode.16-17 In Hong 
Kong, a naturalistic longitudinal follow-up study of 93 
first-episode psychosis patients found that relapse rates 
were 21%, 33%, and 40% in the first, second and third 
year respectively.18 Conclusions drawn from naturalistic 
studies, however, failed to exclude the fact that the high 
relapse rate is a result of medication discontinuation 
where it is not uncommon in patients with psychotic 
disorders.19-20 
In contrast,  double-blind randomised placebo-
controlled trials where discontinuation was controlled, 
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have shown that early discontinuation of antipsychotics 
therapy results in more relapses at 1 year: 63% vs 38%;21 
61% vs 27%;22 41% vs 0%.23 In Hong Kong, relapse was 
studied in a randomised controlled trial on remitted 
first-episode psychosis patients who have been on 
maintenance medication for at least 1 year. It was found 
that relapse rates for those discontinuing medication 
was 79% while continuing medication was 41%.24 These 
findings all point to the importance of continuing 
medication in preventing relapse. 
Consideration of Medication 
Discontinuation
Discontinuing medication is tempting and seems 
logical  to many patients when their  psychotic 
symptoms have subsided, and is consistent to our usual 
conceptualisation of recovery. Although antipsychotic 
maintenance treatment seems to be effective in 
preventing relapse,25-26 controlled studies suggested 
that the subsequent rate of relapse could be substantial 
even on maintenance medication.21-24 Long-term 
maintenance therapy is also increasingly recognised 
as a costly option, as it could lead to substantial long 
term metabolic or neurological side-effects, as well as 
psychological and economic consequences.27 The clinical 
decision on whether to continue the medication is hence 
complex. To patients and their families, the uncertainty 
and psychological burdens surrounding potentially 
lifelong continuation of medication may also be 
substantial. In brief, medication discontinuation should 
be a joint and planned decision involving the patients, 
the carers and the clinicians. The clinicians should 
discuss openly with the patients all the possible options 
and consequences, and also look beyond the short-term 
risk and focus on the long-term health risks and benefits 
for the patient.  After all, there is a small proportion of 
patients who could potentially remain relapse free even 
without maintenance medication.
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Rationale for Early Intervention for 
People with High Risk of Developing 
Psychosis
Psychotic disorders (including schizophrenia and its 
related disorders) involve complex neurobehaviour 
dysfunction, influenced by genetic and environmental 
factors affecting up to 3% of the population17. They 
constitute one of the highest disease burden globally 
and locally. Schizophrenia and its related psychotic 
disorders ranked globally amongst the top ten leading 
causes of disability-adjusted life years (DALYS)(WHO 
2001). The conditions inflict devastating consequences 
for youths and adults at the most productive years 
in their lives. It is estimated that each year 1000- 2000 
individuals in Hong Kong develop a psychotic disorder 
for the first time in their lives. Despite progress in the 
development of medications with fewer side effects, the 
treatment often cannot alleviate the disability associated 
with this chronic form of illness. Deficit symptoms and 
cognitive impairment, which appear to be the greatest 
determinants of disability, remain largely beyond the 
reach of current forms of treatment. The treatment 
outcome is often poor and associated with extensive 
cost, burden, morbidity and mortality. Identification 
and treatment of psychotic disorders is a priority for 
most public health services worldwide. 
Emerging evidence suggests that much of the disability 
associated with psychotic illnesses, particularly 
schizophrenia, develops long before the onset of 
frank psychosis. This pre-onset or prodromal period 
is characterised by non-specific symptoms such as 
depressed mood and anxiety as well as sub-threshold 
symptoms5,23. Cortical changes during this period are 
associated with cognitive, social and motivational 
dysfunctions10, and are difficult to reverse even if the 
first psychotic episode  is successfully treated8,10. The 
prodromal period is therefore potentially important for 
early intervention and the possible prevention of the 
development of the psychotic disorders.
However, a major challenge has been to prospectively 
identifying the prodromal phase, particularly given the 
non-specific nature of prodromal symptoms21. Subjective 
cognitive impairment disturbances known as “basic 
symptoms” have been described by the German Early 
Detection Team and found to be good predictors for 
onset of psychosis4,16. McGorry et al. introduced the term 
“At Risk Mental State”, implying that the sub-threshold 
syndrome can be regarded as a risk factor for the 
subsequent development of psychosis, but that the onset 
of psychosis is not inevitable21,22. The operationalised 
“at risk mental state” described 3 subgroups: (1) 
genetic risk in combination of functioning decline, 
(2) Attenuated positive psychotic symptoms, and (3) 
Transient psychotic episode. Several studies conducted 
internationally in recent years using the criteria yielded 
an average 1 year conversion rate of 36.7% in high risk 
subjects who did not receive antipsychotic treatment15.
Several clinical trials have been conducted to evaluate 
the efficacy of interventions in reducing the transition 
rate to psychosis over the recent few years. The 
interventions used included the combined cognitive 
behavioural therapy and antipsychotic medication11, 
antipsychotic medication alone9, cognitive behaviour 
therapy alone14 and essential fatty acids1. These 
studies demonstrated that psychiatric symptoms and 
psychosis onset can be delayed by specific intervention. 
Several clinical trials on the high risk samples have 
been initiated recently. The intervention agents use of 
these ongoing studies include antidepressants, mood 
stabalisers, methyglycine Ethyl-EPA, case management, 
cognitive training and cognitive behavioural therapy3 
Increasing evidence has demonstrated high rates of 
psychotic like experiences exist in community cohorts18 
and reduction in the transition rate to psychosis 
internationally23. These findings and consequently higher 
false positive rates mean that safer and more benign 
interventions must be offered as the first line treatment to 
these high risk people.
Local Scene-Clinical Aspects
Early Assessment Service for Young People with Psychosis 
(EASY) was established in Hong Kong in 2001. It is a 
population wide early intervention service with an annual 
average of 600 new cases targeted at age 15-252. The 
referrals are open and direct, derived from educational 
settings, youth services, adolescent medical centres, 
primary care, general health services, mental health 
professionals and hotlines. Among the EASY referrals, 
those with first episode psychosis will receive phase 
specific intensive comprehensive treatment; those who are 
not frankly psychotic, but are judged to be “high risk” by 
the assessing psychiatrist will receive non-specific need 
based treatment  while being monitored regularly. Up 
until this stage, the EASY does not have an operationised 
inclusion criteria for the “high risk” cases. The defined 
“high risk” cases are based on clinical assessment by the 
individual psychiatrist in the EASY team.
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Local Scene-Research Aspects
A naturalistic prospective study was conducted in 2002 
in one of the EASY centre (EASY-KCH Clinic) with 
the aim to assess the rate of transition to psychosis in 
a high risk group. Between 1st June 2002 and 30th April 
2003, there were a total of 256 referrals made to the 
EASY-KCH Clinic, among which 153 were psychotic 
and they were treated accordingly. With the remaining 
103 subjects, 67 met the operationalised CAARMS “At 
risk Mental State”21,22 criteria, and 62 of them consented 
to participate in the project. Over a 6 month follow up 
period, 18 subjects (29%) met the criteria for a psychotic 
disorder. In addition, significant differences were found 
in the intake symptomatology and functioning scores 
between the group that ultimately became psychotic 
and the group that did not6. At two-year follow up, 45% 
of the group made transition to psychosis. 
The study results indicate that it is possible to identify 
a sub-sample of the Hong Kong population with a high 
rate of transition to psychosis (29%) within 6 months 
and 45% of the identified high-risk subjects developed 
psychosis within two years. The identified high risk 
subjects had moderate levels of functional decline and 
psychopathology at the study intake. A lengthy delay 
was found between the onset of symptoms and the 
study intake from 11 days to 6.6 years6.
Challenges and Ethical Issues on Pre-
psychotic Intervention 
With the worldwide vast growing enthusiasm in pre-
psychotic identification and intervention over the past 
decade, people working in the field need to be aware 
of the obstacles and ethical issues surrounding this 
area5. Many of these arise from the genuine problems 
associated with defining the onset in psychiatric 
disorders. The lack of a clear boundary between 
normality and psychotic disorders18 is especially 
relevant during onset as syndromes emerge and 
progress from origins which are indistinguishable from 
normal experiences13.
Misunderstanding the implications of a positive 
diagnostic test  may lead to negative outcomes 
including inappropriate stigmatisation, discrimination 
in employment, and difficulties in obtaining life 
insurance24. Communicating one’s risk status to others 
can deprive social and occupational opportunities in 
several ways including overt discrimination; self stigma 
presents another potential hazard to the subjects’ 
psychological and social development24. Self stigma 
was seen related to low self esteem, diminished self-
efficacy and abandonment of developmental challenges 
and occupational goals. In addition, growing concerns 
regarding long term and short term consequences 
of exposing a developing brain to drugs need to be 
considered25. The problems raised  by false negatives are 
less frequently mentioned9,25. However, being wrongly 
reassured may also be a harmful consequences of early 
detection.
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Introduction
The management of schizophrenia and its related 
disorders has advanced substantially in the past 
decades, with the use of better tolerated antipsychotics 
and the introduction of specialised intervention 
programmes in many parts of the world. Patients’ 
outcome can be particularly improved when treated 
early within the critical period.1, 2 
Early identification of schizophrenia is thus crucial. In 
countries with low to medium level of resources, the 
World Health Organization (WHO) and International 
Early Psychosis Association (IEPA) recommend 
surveying high-risk population groups or instituting 
surveillance for early psychosis in the community.3 It is 
now recognised that in the majority (68%) of cases, the 
index psychotic episode is preceded by a prodromal 
stage.4 During this stage, subthreshold psychotic 
symptoms and other nonspecific early signs may be 
observed. These early signs and symptoms may serve as 
flags for identifying at-risk individuals clinically. 
Subthreshold Psychotic Symptoms
Sometimes referred to as attenuated psychotic 
symptoms or brief limited intermittent psychotic 
symptoms (BLIPS), these are mental problems that 
occur close to the onset of a full-blown disease, either 
with a lower intensity or of a shorter duration (resolving 
without antipsychotic medication) than those seen in 
frank psychosis. 
According to the Comprehensive Assessment of At-Risk 
Mental States (CAARMS),5  these symptoms can be 
grouped under four dimensions as listed in the Table. 
Attenuated psychotic symptoms are defined as those 
experienced occasionally at a moderate to severe (but 
not psychotic) intensity. When these are experienced at a 
severe to psychotic intensity but remitted spontaneously 
within 1 week, BLIPS is said to be present.
Table. Symptom dimensions in the CAARMS criteria for 
attenuated psychotic symptoms or BLIPS.5
Dimensions Symptoms
Unusual thought 
content
Delusional mood and perplexity, ideas of reference, 
bizarre ideas (e.g. passivity, thought insertion, withdrawal, 
broadcasting, or mind reading)
Non-bizarre 
ideas
Suspiciousness or persecutory, grandiose, somatic, guilt, 
nihilistic, jealous, religious, and erotomanic ideas
Perceptual 
abnormalities
Visual, auditory, olfactory, gustatory, tactile, and somatic 
changes
Disorganised 
speech
Subjective changes (e.g. difficulty with speech, trouble finding 
words, not getting to the point, difficulty in understanding, 
repeating words of others, staying silent) and objective 
changes (e.g., incorrect words, circumstantial, tangential, 
vague, overly abstract or concrete, use of strange words)
Nonspecific Early Signs  
Sometimes referred to as “basic symptoms”, these are 
subtle and often subjective changes in cognition, affects, 
drive, stress tolerance, sleep, speech, perception, and 
motor actions, which are believed to be early expressions 
of the underlying physiological disturbances for later 
development of psychosis.
A wide range of early signs has been proposed, 
including for example coenaesthesic symptoms and 
cognitive abnormalities,6 changes in the sense of self 
and the world,7 disorder of selective attention,8 affective-
dynamic disturbances (e.g. impaired tolerance to certain 
stressors or novel demands), and body perception 
disturbances (e.g. numbness, bodily sensations 
migrating through the body),9 to name a few.
Researchers have been trying to narrow down the list 
by identifying those most frequently precede onset 
of psychosis. Current data from prospective and 
retrospective studies4,10,11 suggest the following: reduced 
concentration and attention; reduced motivation and 
anergia; depression; slowness; sleep disturbances; 
anxiety and worrying; social withdrawal; lack of 
self-confidence; suspiciousness; deterioration in role 
functioning; irritability and restlessness; thought 
interferences, preservation, pressure, or blockages; 
disturbances of receptive language; decreased ability to 
discriminate between ideas and perception and between 
phantasy and true memory; derealisation; unstable 
ideas of reference; and visual and acoustic perception 
disturbances. 
Discussion
While diagnosis of frank psychosis may be less 
problematic, early signs and symptoms suggestive 
of later psychosis are comparatively elusive. The 
nonspecificity of many of these features means possible 
overlaps with normal adjustment problems or other 
psychiatric conditions (e.g. depression).4 At present, 
a set of early signs and symptoms that are invariably 
followed by psychosis onset is yet to be identified. 
Despite these problems, early detection and monitoring 
of help-seeking individuals presenting with risk 
features remains an important strategy to ensure timely 
intervention should they become ill. This is especially 
true when considered together with other risk factors 
(e.g. family history, age) and traits (e.g. schizotypy). 
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While routine screening of risk features may not be 
feasible, a number of self-assessment tools have been 
made available. Some of these, including the Psychosis 
Screening Questionnaire (PSQ)12 and Prodromal 
Questionnaire, Brief Version (PQ-B),13 have been 
translated and adapted for use by local organisations 
and early psychosis intervention projects, and can be 
accessed via the websites www3.ha.org.hk/easy,  www.
episo.org and www.jcep.hk. Suspected psychosis entails 
a more thorough mental state assessment. 
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A 50-year-old woman complained of one year’s history 
of insidious onset of this mildly itchy skin rash around 
her upper back (Fig. 2a), proximal limbs (Fig. 2b) and 
her face extensively. The skin rash was associated 
with weight loss.  Complete blood picture, liver and 
renal function tests were normal except a raised ESR 
of 70mm/hr.  Skin biopsy at the papular lesion showed 
increased mucin deposition within the dermis with no 
epidermal change.  There was an increase in irregularly 
arranged spindle cells in the dermis identified as dermal 
fibroblasts with intervening dermal fibrosis. 
Questions:
1.What is your provisional diagnosis or 
   differential diagnoses?
2.What other important specific tests you would like 
   to order for investigating her weight loss?
3.How will you manage this patient?
Fig 2: Skin lesion at (a) upper back and (b) right upper arm
(See P. 25 for answers)
Dermatological Quiz
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Introduction
Although substance abuse disorder is a common 
comorbidity of mental illness, it is particularly prevalent 
in patients with schizophrenia1. One of the most 
widely held explanations for this phenomenon is the 
self-medication hypothesis2,3 which is based on the 
negative reinforcement theory; that is the behaviour 
is reinforced by the purposeful removal of aversive 
experience, which could be disease symptoms and/
or side effects of the medication. However recent 
studies on the neuropathology of schizophrenia and 
addiction behaviour have provided an alternative 
hypothesis. It has been suggested that there is a 
common neuropathological substrate independently 
causing the manifestation of symptoms of schizophrenia 
and addiction disorder. There are substantial literature 
suggesting that the mesolimbic dopamine (DA) 
system is a major substrate for reinforcing effects of 
substance and involving in mediating drug craving. 
The mesolimbic DA system is also an important system 
involved in the neuropathology of schizophrenia4. In 
fact, studies of pharmacological models of psychosis 
using different psychoactive substances have provided 
further evidence on this hypothesis and also improve 
our understanding of the biological basis of psychotic 
symptoms and the disorder as a whole. This article aims 
at providing further understanding of the dopamine 
hypothesis of schizophrenia through brief discussions 
on two commonly studied pharmacological models of 
psychosis – Amphetamine and Ketamine.
Dopamine Hypothesis of Psychosis – 
Amphetamine Model of Psychosis
It  was first  proposed that the hyperactivity of 
dopamine transmission is responsible for the psychotic 
symptoms5. This was supported by the correlation 
of the clinical dose of antipsychotic drugs and their 
potency in blocking the dopamine D2 receptors6,7 
mainly in the subcortical regions. Further evidence 
has been accumulated using amphetamine challenge. 
Amphetamine is an indirect-acting dopamine agonist 
which increases dopamine levels in the synaptic cleft 
by inhibiting the action of the dopamine transporter8. 
High dose repeated administrations of amphetamine 
to normal volunteers result in paranoid symptoms and 
formal thought disorders9. More recently, studies using 
imaging techniques such as PET and Single Photon 
Emission Computed Tomography (SPECT) during 
amphetamine challenge have shown that there is an 
elevation in the binding of dopamine at the D2 receptors 
after amphetamine challenge in schizophrenic patients 
compared to age-matched controls, and the elevation is 
associated with positive psychotic symptoms10-12. 
However, there is little indication that amphetamine 
psychosis provides a model of negative symptoms. 
Some studies have shown a decreased dopamine 
turnover13,14 and hence raised a possibility of hypoactive 
dopamine system involvement. This has led to the 
revision of the classical hypothesis of schizophrenia. The 
hyperactive subcortical mesolimbic dopamine projection 
(hyperstimulation of the D2 receptors) is associated 
with positive psychotic symptoms; while hypoactive 
mesocortical dopamine projection (hypostimulation of 
D1 receptors) is associated with negative and cognitive 
symptoms15,16.  Consistent with this, pre-clinical 
studies have demonstrated that a deficit of dopamine 
transmission at the D1 receptors in the prefrontal cortex 
might be implicated in cognitive impairments and 
negative symptoms of schizophrenia17. 
The possibility of coexistence of both hypodopaminergic 
and hyperdopaminergic states in the same condition 
has raised the possibility of involvement of other 
neurotransmitters as modulators. Consistent with this 
is the observation that in addition to amphetamine, 
many other psychoactive agents can produce similar 
disturbances in thought process and perception, 
including PCP/Ketamine.
Dopamine and Glutamate - Ketamine 
Model of Psychosis
Ketamine is a structural analogue of phencyclidine 
(PCP). Both PCP and ketamine are dissociative 
anaesthetic agents and are non-competitive antagonists 
of the N-methyl-D-aspartic acid (NMDA) subtype 
of glutamate receptors.  It  was observed that a 
subanaesthetic dose of PCP (0.1 mg/kg) could induce 
a schizophrenic-like psychotic state in healthy human 
subjects18. The symptoms include positive psychotic 
symptoms (such as hallucinations, delusions and 
thought disorder), negative symptoms (such as apathy), 
and cognitive symptoms (such as inability to maintain 
cognitive sets, planning deficits and concrete ideation). 
PCP non-competitively blocks the ion flow through 
the NMDA-sensitive glutamate receptor ionophore19. 
Because of the neurotoxic effects of PCP determined 
by studies in rodents20,21, the use of PCP in studies in 
humans is considered unethical. The structural analogue 
of PCP, ketamine, provides an alternative model of 
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psychosis for use in human subjects. Further studies 
have been carried out in recent years both in healthy 
volunteers and schizophrenic patients to examine this 
model of psychosis. In schizophrenic patients, ketamine 
briefly exacerbated existing symptoms that patients 
had experienced before and some of them had delayed 
or prolonged effects; patients did not experience new 
symptoms that they had not previously encountered as 
part of their illness22-24. 
In healthy volunteers, ketamine transiently produces a 
range of dose-related psychotomimetic and cognitive 
effects that include positive symptoms, negative 
symptoms, mood changes and thought disorders22, 24-
29. Dissociative symptoms are prominent and these may 
be important early features of the illness. Cognitive 
dysfunction, consistent with the impairments seen in 
patients with schizophrenia, are also evident in healthy 
subjects following exposure to ketamine, including 
impairment in attention, memory, abstract thinking, 
planning and judgement24, 25, 27, 30-39. 
The NMDA receptor is one of the receptors present 
on the GABAergic interneurons which modulate the 
excitatory pathways. The antagonistic effect of ketamine 
on these NMDA receptors reduces the GABAergic 
inhibitory action and hence disinhibits the excitatory 
pathways, including dopamine, glutamatergic, serotonin 
and norepinephrine, and cholinergic systems40. The 
understanding of the psychogenic effects of ketamine 
and neuropathological process supports the hypothesis 
that endogenous hypo-function of the NMDA receptor 
may be a key component of the pathophysiology of 
psychosis40-43.
This hypothesis has received further supports form 
the preclinical studies. It was shown that acute 
administration of NMDA receptor antagonists increased 
the release of dopamine in striatum and nucleus 
accumbens43-45. PET imaging of 11C-raclorpiride binding 
in human subjects showed ketamine increased striatal 
dopamine release46 and the magnitude of its increase 
correlated with ketamine induced psychosis47,48. 
Preclinical studies also showed acute administration of 
NMDA antagonists increased dopamine transmission in 
the prefrontal cortex13,43,49,50. It was found that ketamine 
increased cortical dopamine levels particularly in the 
posterior cingular and dorsolateral prefrontal cortex in 
human subjects51. 
The above evidence supports the idea that changes 
in dopaminergic function are closely associated with 
changes of the glutamate system, particularly via the 
NMDA receptors: this is a dynamic and reciprocal 
relationship, with evidence of glutamatergic modulation 
of dopamine,  as described above,  but equally, 
dopaminergic influences on glutamate: D2 receptor 
stimulation inhibits NMDA-mediated glutamate 
transmission whereas D1 receptor stimulation facilitates 
it52, 53. 
Conclusion
The study of the amphetamine model of psychosis 
supports the role of dopamine in the neuropathological 
process of psychosis. Studies of ketamine model of 
psychosis further suggest the modulatory role of 
glutamate in this process. It is clear that studying 
the psychogenic effects of different substances and 
their associated neuropathological changes, the 
pharmacological models of psychosis, provides 
us with a window to further explore the complex 
neuropathological process of psychosis. One of the 
other pharmacological models being studied actively is 
the delta-9-tetrahydrocannabinol (THC) model, which 
is a major component of cannabis. These different 
models have provided us with more detailed insight 
into the interaction of other neural substrates with 
dopamine and the relationship with the symptom 
formation. This would be an important tool to enhance 
our understanding of the neuoropathological process of 
psychosis. 
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The 5th Annual Scientific Meeting – Hong 
Kong Society of Biological Psychiatry 
(19-20 March 2011) 
Prof. Siu-wa TANG
President, Hong Kong Society of Biological Psychiatry 
Psychiatry is medicine of the brain. The human brain is 
the most complex organ in the human body and we are 
far from understanding many of its functions. Because 
of this, clinical psychiatry has generally concerned 
itself with the most serious brain disorders which 
led to major and observable disturbances in human 
behaviour, such as schizophrenia and dementia. Terms 
such as “crazy”, “retarded” or “mental disorders” were 
often used by non-clinicians to describe unfortunate 
patients suffering from these serious disorders. Treating 
“crazy behaviour” was perceived as equivalent to 
what psychiatry was about. This biased and ignorant 
perception of psychiatry has resulted in the prejudiced 
attitude towards psychiatry for many years. As a result, 
the brain was an “untouchable” organ. The brain could 
never go wrong. Although the brain is a vital organ, 
brain examination has never been part of a general 
routine physical examination. 
Advances in neurosciences and brain medicine have 
now begun to change the scope of psychiatry. Treatment 
of major depression, anxiety disorders, psychosomatic 
disorders, ADHD and many behavioural problems 
related to disorders of brain function have rapidly 
expanded the field of clinical psychiatry. One of the most 
significant changes in psychiatry in the last decade has 
been in the field of social psychiatry. Social psychiatry 
used to be in the backwater of medicine. Though 
important to the understanding of abnormal human 
behaviour and a very interesting subject in itself, it was 
difficult to associate social psychiatry with the biology 
of the brain. It was difficult to relate the knowledge of 
brain medicine, e.g. neurobiochemistry, neuro-psycho-
pharmacology, neurophysiology to the subject matters 
of social psychiatry. 
Research using new biological tools in the past decade 
has revolutionised the understanding of normal and 
abnormal human social behaviour. Presentations by 
Professors Carter, Porges, Yamawaki and Leonard and 
other local researchers in this symposium of the Hong 
Kong Biological Psychiatry represent some of the most 
important works enabling us to understand human 
social interaction such as love, attachments, bonding 
and stress in biological terms. Together, the rapidly 
accumulating volume of work in this field has created 
an international impetus towards an emerging field of 
medicine, which I call “Biological Social Psychiatry”. 
Stress, Inflammation and Mental Illness 
Prof. Brian LEONARD
PhD
Parmacology Department, The National University of Ireland, Galway 
Department of Psychiatry and Psychotherapy, Ludwig Maximilian University, Munich, Germany 
 
Stress causes maladaptive changes in the neurotransmitter, 
immune and endocrine systems which play a major role 
in initiating ill-health and major psychiatric disorders. 
In recent years there has been a paradigm shift in 
our understanding of the inter-relationship between 
the hypothalamic-pituitary-adrenal [HPA] and the 
immune axes. Thus activation, rather than suppression, 
of important aspects of the immune system occurs 
following chronic stress. One of the reasons for this is 
ascribed to the glucocorticoids induced apoptosis of 
hippocampal neurons that occurs as a consequence 
of the desensitisation of central and peripheral 
glucocorticoids receptors. Thus chronic low grade 
inflammation, which results from the stress induced 
activation of peripheral and central inflammatory 
pathways, is central to the pathogenesis of depression 
and schizophrenia and linked to diabetes, cancer, 
asthma, arthritis and cardiovascular disease that are 
frequently co-morbid with these disorders. 
Evidence in support of the inflammation hypothesis of 
major psychiatric disorders was first provided by Smith 
[Med.Hypoth. 35,298-306, 1991] who suggested that the 
symptoms of psychiatric disorders arise from the stress 
and genetically programmed activation of peripheral 
[macrophages/monocytes] and central [microglia, 
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astrocytes and oligodendroglia] macrophages that result 
in the elevation of pro-inflammatory cytokines and 
other inflammatory mediators, such as prostaglandin 
E2, in the blood and cerebrospinal fluid. Thus there is 
an imbalance between the pro- and anti-inflammatory 
arms of the immune system which characterises most 
major psychiatric disorders, changes that are largely 
attenuated following effective treatment. 
The rise in glucocorticoids and pro-inflammatory 
cytokines also results  in  the act ivat ion of  the 
tryptophan-kynurenine pathway whereby tryptophan is 
shunted away from serotonin synthesis to the formation 
of kynurenine and its end-products following the 
activation of indoleamine 2, 3-dioxygenase, by pro-
inflammatory cytokines, and tryptophan dioxygenase, 
by glucocorticoids, respectively. These changes link 
stress and inflammation with the formation of the 
neurotoxic metabolites of the tryptophan-kynurenine 
pathway [3-hydroxykynurenine and quinolinic acid]. 
Further, in the brain the pro-inflammatory cytokines 
activate cyclo-oxygenase and nitric oxide synthase 
thereby increasing the PGE2 and NO concentrations in 
the brain. These add to the inflammatory stress within 
the brain [Leonard and Myint, Neurotox.Res. 10,149-
160,2006]. 
Tis in chronic depression and schizophrenia the 
inflammatory changes, coupled with stress-induced 
hypercortisolaemia which blocks the synthesis of 
neurotrophic factors that normally repair damaged 
neurons, the neurodegenerative pathways predominate 
over the neuroprotective pathways,  Thus i t  is 
hypothesised that chronic stress and inflammation 
are causal ly  associated with the pathology of 
major psychiatric disorders such as depression and 
schizophrenia.  
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Miss Candice TONG
Tel: 2527 8285
1 CME Point
HKMA Kln West Community Network – Lecture Series on Urology (Series 2 & 3) 
Organiser: HKMA Kln West Community Network, Chairmen: Dr. WH WONG & Dr. CP 
CHAN, Speakers: Dr. Pak-ling LIU & Dr. Ming-kwong YIU, Venue: Panda Hotel, Tsuen 
Wan
1:00 pm 
Ms. Sonia CHEUNG 
Tel: 2527 8898
Fax: 2865 0345
FMSHK Executive Committee Meeting  and Council Meeting 
Organiser: The Federation of Medical Societies of Hong Kong, Venue: Council Chambers, 
4/F., Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, Hong Kong
8:00 pm – 10:00 pm 
TUE17
Miss Candice TONG
Tel: 2527 8285
HKMA Shatin Doctors Network - Osteo-arthritis Current Treatment and Beyond
Organiser: HKMA Shatin Doctors Network, Chairman: Dr. Wing-kin MAK, Speaker: Dr. 
Ming-yan LUI, Venue: Royal Park Hotel, Shatin
1:00 pm 
FRI20
Miss. Carman WONG
Tel: 2527 8285
1.5 CME Points
HKMA NTW Community Network – New Advances in Anticholinergic Therapy
Oganiser: HKMA NTW Community Network, Chairman: Dr. Ivan CHUNG, Speaker: Dr. 
Thomas Joo-shium LEE, Venue: Plentiful Delight Banquet, 1/F., Ho Shun Tai Building, 10 
Sai Ching Street, Yuen Long, N.T.
Miss Sophia LAU
Tel: 2527 8285
1 CME Point
HKMA Structured CME Programme with Hong Kong Sanatorium & Hospital Year 
2011 – Refractive and Presbyopia Treatment
Organiser: The Hong Kong Medical Association, Chairmen: Dr. CM CHENG; Dr. HK HO 
& Dr. BL WONG, Speaker: Dr. John S. CHANG Jr., Venue: Central
1:00 pm 
2:00 pm 
Congress Secretariat
Tel: (632) 9274973-74; 
        (632) 9281083; (632) 9292359
Fax: (632) 9292297
E-mail: secretariat@acs2011.org
Website:  www.acs2011.org
18th Asian Congress of Surgery & 37th Philippine College of Surgeons Mid-year 
Convention
Organiser: Asian Surgical Association, Venue: Waterfront Cebu City Hotel & Casino, 
Lahug, Cebu City, Philippines 
Ms. Echo LEUNG
Tel: 3575 8600
Fax: 2301 2414
Email: aiam_hk@yahoo.com
Website: http://www.wcam2011.org
第18屆世界美容醫學大會 
Organiser: Union International de Medicine Esthetigue (UIME), Chairman: 劉洪臣先生, 
Venue: 中國北京市朝陽區北辰東路8號中國北京國際會議中心
THU12
Miss Sophia LAU
Tel: 2527 8285
3 CME Points
HKMA Certificate Course on Family Medicine 2011
Organiser: The Hong Kong Medical Association, Chairman: Dr. CM CHENG; Dr. HK HO 
& Dr. BL WONG, Speakers: Dr. Alvin Yee-shing CHAN & Dr. Ka-yeung FONG, Venue: 
Queen Elizabeth Hospital, Kowloon 
2:00 pm
Miss Alice TANG / 
Miss Sharon HUNG
Tel: 2527 8285
HKMA Squash Tournament
Organiser: The Hong Kong Medical Association, Chairman: Dr. TY CHAN Venue: 
Kowloon Cricket Club
2:00 pm
SUN15
Miss Sophia LAU
Tel: 2527 8285
2 CME Points
Refresher Course for Health Care Providers 2010/2011
Charimen: Dr. CM CHENG; Dr. HK HO & Dr.  BL WONG, Speaker: Ka-chung WONG, 
Venue: OLMH
2:30 pm 
SAT14
Dr. Gilberto LEUNG
Tel: 2255 3368   Fax: 2818 4350
1.5 points (College of Surgeons of 
Hong Kong)
Hong Kong Neurosurgical Society Monthly Academic Meeting –Anticoagulation and 
Antiplatelet Therapy in Intracranial Stenting : Update and Consensus
Organiser: Hong Kong Neurosurgical Society, Chairman: Dr. Peter PANG, Speaker: Dr. 
Calvin MAK, Venue : Seminar Room, Ground Floor, Block A, Queen Elizabeth Hospital
7:30 am
WED11
MON9
Dr. Hing-hoi HUNG / 
Ms. Tammy HUNG 
Tel: 2958 6006 / 9609 6064
Fax: 2958 6076 / 8344 5115
1 CME Point (The College of 
Surgeons of Hong Kong) 
Learning Experience from UK – FRCS (Urol) Revision Course 
Organiser: Hong Kong Urological Association, Chairman: Dr. Chi-wai FAN, Speakers: 
Dr. Vera CHUNG; Dr. Thomas LAM & Dr. Stanley KAN, Venue: Seminar Room, G/F, 
Block A, Queen Elizabeth Hospital, Kowloon 
7:30 – 8:30 pm 
Ms. Candy YUEN
Tel: 2527 8285
HKMA Choir Rehearsal
Organiser: The Hong Kong Medical Association, Chairman: Dr. YS CHAN & Dr. YM 
NG, Venue: GP1, HKCC 
8:00 pm 
WED
4
Miss Carman WONG & 
Miss Candice TONG
Tel: 2527 8285
Certificate Course on Management of Drug Abuse Patients for Family Doctors (HK 
Island) - Session 1 to Session 4
Organisers: HKMA Beat Drugs Action Committee; HKMA CW&SCN and HKMA 
HKECN, Speakers: Various, Venue: The Hong Kong Medical Association Central 
Premises, Dr. Li Shu Pui Professional Education Centre, 2/F., Chinese Club Building, 
21-22 Connaught Road Central
12:45 pm 
TUE3
Miss Sophia LAU
Tel: 2527 8285
1 CME Point
HKMA Tai Po Community Network - Puberty & Pubertal Disorders in Children
Organiser: HKMA Tai Po Community Network, Chairman: Dr. SH CHIU, Speaker: Dr. 
Chak-man YU, Venue: Tai Po
1:45 pm 
Ms. Sonia CHEUNG 
Tel: 2527 8898 
Fax: 2865 0345
FMSHK Officers’ Meeting
Organiser: The Federation of Medical Societies of Hong Kong,   Venue: Gallop, 2/F., 
Hong Kong Jockey Club Club House, Shan Kwong Road, Happy Valley, Hong Kong 
8:00 pm – 10:00 pm
SUN
Miss Alice TANG & 
Miss Sharon HUNG
Tel: 2527 82851
HKCC 19th Annual Scientific Congress
Chairman: Dr. CS CHIANG, Venue: Sheraton Hotel & Towers, Kowloon
Date  / Time Function Enquiry / Remarks
8:00 am
Miss Alice TANG / 
Miss Sharon HUNG
Tel: 2527 8285
HKMA Dragon Boat Team Practice Session
Organiser: The Hong Kong Medical Association, Chairman: Dr. CY YAM & Dr. PY 
CHENG, Venue: Stanley Main Beach or Sai Kung 
SUN8
Ms. Candy YUEN
Tel: 2527 8285
HKMACF Charity Concert
Organiser: HKMA Charitable Foundation, Venue: City Hall
8:00 pm 
FRI6
Department of Surgery, Hong 
Kong Sanatorium & Hospital
Tel: 2835 8698   Fax: 2892 7511
1 CME Point (Active)
Joint Surgical Symposium - Management of Benign and Malignant Anorectal Diseases
Organisers: Department of Surgery, The University of Hong Kong & Hong Kong 
Sanatorium & Hospital, Chairman: Dr. Angus CW CHAN, Speakers: Dr. Jensen POON 
& Dr. Siu-Hung LO, Venue: Hong Kong Sanatorium & Hospital
8:00 am - 9:00 am
Ms. Christine WONG
Tel: 2527 8285 
Council Meeting
Organiser: The Hong Kong Medical Association, Chairman: Dr. CHOI Kin, Venue: 
Wanchai
9:00 pm 
(8,15,22,29)
(11,18,29) 
(16,23,30)
(13,14)
(31)
(13,14,15)
Calendar of Events
    24
VOL.16  NO.5  MAY  2011
Course / Meeting
Hong Kong Surgical Forum – Summer 2011
Organiser: Department of Surgery, The University of Hong Kong; Queen Mary Hospital & Hong Kong Chapter of American 
College of Surgeons, Venue: Underground Lecture Theatre, New Clinical Building, Queen Mary Hospital, Pokfulam, Hong Kong, 
Enquiry: Forum Secretary, Hong Kong Surgical Forum, Tel: 2255 4882 / 2255 4886, Fax: 2819 3416, Email: hksf@hku.hk, Website: 
http://www3.hku.hk/surgery/forum.php 
16/7/2011
Upcoming Certificate Courses of the Federation of Medical Societies of Hong Kong
5/5/2011 - 9/6/2011
12/7/2011 - 16/8/2011
Medical, Health Professionals and 
General Public 
Healthcare Workers 
9 CNE Points; CME/CPD 
Accreditation in application
9 CNE Points; CME/CPD 
Accreditation in application
Certificate Course on Current 
Management of Common Head & 
Neck Cancers 
Certificate Course on 
Occupational Hygiene Practice 
C172
C178
Date Course No Target ParticipantsCourse Name CME/CNE 
Miss Sophia LAU
Tel: 2527 8285
1 CME Point
HKMA Tai Po Community – “Treatment Strategies in Type 2 Diabetic Patient to 
Avoid Hypoglycemia”
Organiser: HKMA Tai Po Community Network, Chairman: Dr. SH CHIU, Speaker: Dr. 
Alice Pik-shan KONG, Venue: Tai Po 
1:00 pm
Miss Candice TONG
Tel: 2527 8285
1 CME Point
HKMA Yau Tsim Mong Community Network - Quadrivalent HPV Prevention - More 
than Cervical Cancer Prevention
Organiser: HKMA Yau Tsim Mong Community Network, Speaker: Dr. Kar-fai TAM, 
Venue: Eaton Hotel 
1:00 pm
Dr. Fanny Wai-san KO / Dr. 
Arthur Chun-wing LAU
Tel: 2632 2785    Fax: 2637 5396
1.5 – 2 CME Points 
(1)A Sleepless Night (2) Bad News!? Black News!
Organiser: Hong Kong Thoracic Society/American College of Chest Physicians (HK & 
Macau Chapter), Chairpersons: Dr. Jamie LAM & Dr. Chi-fong WONG, Venue: LG1, 
Lecture Room, Ruttonjee Hospital, Hong Kong 
6:30 pm – 8:00 pm
TUE24
Miss Carman WONG
Tel: 2527 8285
HKMA NTW Community Network – Treatment Option for Major Depressive Disorder
Organiser: HKMA NTW Community Network, Chairman: Dr. Lambert Lam-fung CHAN, 
Speaker: Dr. Ka-lik KWAN, Venue: Plentiful Delight Banquet, 1/F., Ho Shun Tai Building, 
10 Sai Ching Street, Yuen Long, N.T.
1:00 pm
THU26
Miss Alice TANG &
Miss Sharon HUNG
Tel: 2527 8285
HKMAPS 2nd Photo Competition & Sharing Session 2011
Organiser: The Hong Kong Medical Association, Chairman: Dr. A PANG, Venue: 
Wanchai
2:00 pm 
SUN29
Miss Alice TANG & 
Miss Sharon HUNG
Tel: 2527 8285
HK International Dragon Boat Race Local Team Manager Meeting
Chairman: Dr. CY YAM & Dr. PY CHENGMON30
Ms. Vanessa WONG
Tel: 2871 8773   Fax: 2785 1850  
3 CME (Category A)
2011 Paediatric Update No. 1 Seminar on Infant and Young Child Feeding 
Organiser: Hong Kong College of Paediatricians, Chairman: Dr. Sik-nin WONG & Dr. 
Shirley LEUNG, Speakers: Various, Venue: Lecture Theatre, Hospital Authority Head 
Office, M Floor
SUN22
Date  / Time Function Enquiry / Remarks
Conference Secretariat 
Tel: 2559 9973     Fax: 2547 9528
Email: roc2011@icc.com.hk 
12th Regional Osteoporosis Conference 2011
Organiser: Osteoporosis Society of Hong Kong & Hong Kong Society of Rheumatology, 
Speakers: Various, Venue: Hong Kong Convention and Exhibition Centre 
(22)
SAT21
Miss Candice TONG
Tel: 2527 8285
HKMA Yau Tsim Mong Community Network & Kowloon Central Cluster - Certificate 
Course Bringing Better Health to the Community (Lecture 1)
Organiser: HKMA Yau Tsim Mong Community Network & Kowloon Central Cluster, 
Chairman: Dr. CP HO, Speakers: Dr. Gia Hung NGUYEN & Dr. Chun LAM, Venue: 
Queen Elizabeth Hospital
Miss Alice TANG & 
Miss Sharon HUNG
Tel: 2527 8285
HKMA Youth Committee Career Seminar
Organiser: HKMA Youth Committee, Chairmen: Dr. CF PONG & Dr. PY SIN, Venue: 
The Hong Kong Medical Association Central Premises, Dr. Li Shu Pui Professional 
Education Centre, 2/F., Chinese Club Building, 21-22 Connaught Road Central, Hong 
Kong 
1:00 pm 
3:00 pm 
SAT28
Ms. Gary WONG
Tel: 3513 4821
1.5 CME Points
HKMA – KLN East Community Network; HA – UCH; HKCFP - CME Course for 
Health Personnel 2011
Organiser: The Hong Kong Medical Association, Chairman: Dr. Man-fuk LEUNG, 
Speaker: Dr. Kwok-fai HUI, Venue: Lecture Theatre, G/F., Block F, United Christian 
Hospital, Kowloon 
1:30 pm 
Calendar of Events
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Answer to Dermatological Quiz
1.
2.
3.
This middle aged woman presented with this quite 
asymptomatic extensive multiple shiny waxy a few 
millimetre small discrete whitish to skin-coloured 
papules which coalesced into larger papules/ small 
plaques affecting her face, upper back and limbs. The 
clinical differential diagnoses should include various 
forms of cutaneous mucinosis, lichen amyloidosis, 
scleredema of Buschke, scleroderma, eruptive xanthoma, 
eruptive syringoma and generalised myxoedema. 
Coupled with the history of systemic upset and histology 
showing increased dermal mucin deposition and 
fibroblast proliferation, the clinicopathological diagnosis 
of scleromyxoedema, which is a generalised form of 
cutaneous mucinosis, can be made. 
Primary cutaneous mucinosis is a heterogenous group 
of disorders in which an abnormal amount of mucin 
accumulates in the skin with unknown pathophysiology. 
The widespread distribution form, as demonstrated in 
this patient, is known as scleromyxoedema. It presents 
with generalised shiny waxy small discrete whitish 
to skin-coloured papular eruptions with or without 
sclerodermoid features.  Histologically, this rare disease 
is characterised by a triad of a) diffuse deposits of mucin 
in the dermis b) an increase in collagen deposition c) 
a marked proliferation of dermal fibroblasts arranged 
irregularly.  
Scleromyxoedema is almost always associated with 
paraproteinaemia.  The monoclonal gammopathy 
is usually Ig G with gamma light chains. Less than 
10% of scleromyxoedematous patients progress to 
multiple myeloma. As a result, a malignancy screening 
especially with immunoglobulin level and serum protein 
electrophoresis confirmed the presence of monoclonal 
gammopathy in this patient.  Bone marrow aspiration did 
not show any myeloma changes.
There is  no well  proven effective treatment for 
scleromyxoedema because of the rarity of the disease. 
The commonly used approach is to treat the underlying 
paraproteinaemia or haematological malignancies which 
may alleviate the cutaneous mucinosis. In patients with 
confirmed myeloma, monthly melphalan combined 
with various drugs such as thalidomide, systemic 
steroids, and/or autologous haematopoietic stem cell 
transplantation are employed.  A similar strategy has 
begun to be adopted for treating scleromyxoedema. 
However, the risks of marrow suppression and sepsis 
should be carefully weighed against the benefits.  Other 
modalities which have been reported effective anecdotally 
include topical and intralesional hyaluronidase, PUVA, 
UVA1, systemic retinoids, electron-beam radiation, IVIg, 
plasmapheresis, extracorporeal photochemotherapy, 
cyclosporine, and granulocytes colony-stimulating factor.
Dr. Ka-ho LAU 
MBBS(HK), FRCP(Edin, Glasg), FHKCP, FHKAM(Med)
Yaumatei Dermatology Clinic, Social Hygiene Service
 The Federation of Medical Societies of Hong Kong
 4/F Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, HK
 Tel: 2527 8898           Fax: 2865 0345
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